Aurobindo Gets USFDA Final Nod for Esomeprazole Magnesium DR Capsules | CORPORATE ETHOS

Aurobindo Gets USFDA Final Nod for Esomeprazole Magnesium DR Capsules

By: | October 17, 2017
aurobindo

Oct 17: Hyderabad-based drug maker Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20mg.

According to the company, the product is a therapeutic equivalent generic version of AstraZeneca’s Nexium 24HR capsules. The product will be launched immediately, it said.

“Nexium 24HR (Esomeprazole Magnesium) capsules are indicated to treat frequent heartburn (occurs 2 or more days a week). The approved product has an approximate annual sales in excess of $300 million, according to IRI database,” the company added.

This is the 127th ANDA (including 23 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India, used for manufacturing oral products. Aurobindo now has a total of 335 ANDA approvals (296 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

Shares of the company were trading at Rs 769, up 1.50% from the previous closing of Rs 757.60, on BSE at 11.09 am today.